tbuckley/cabot-search huggingface dataset:
208P: Pathological response after neoadjuvant chemotherapy (chemo) and nivolumab (NIVO) in resectable non-small cell lung cancer (NSCLC): Initial results from a French multicenter real-world (rw) retrospective study
Authors: N. Girard, Q. Thomas, B. Godbert, E. Grolleau, P. Demontrond, V. Avrillon, O. Bylicki, K. Bouaziz, P. Salamoun Feghali, F. Brellier, O. Tifoun, S. Lucherini, L. Vo, A. Prudent, H. Curcio, X. Quantin, N. Hegarat, F. Lucibello, M. Carton
Journal: Journal of Thoracic Oncology (2025)
193P: Association of effective dose to immune cells with outcomes after definitive chemoradiotherapy and durvalumab in non-small cell lung cancer: A multi-center study
Authors: I. Averbuch, A. Raphael, O. Icht, P. Blumenfeld, S. Appel, A. Allen, M.T. Moskovitz, D.J. Reinhorn
Journal: Journal of Thoracic Oncology (2025)
196P: 5-year survival and safety of stereotactic ablative radiotherapy in unresectable locally advanced non-small cell lung cancer patients unfit for concurrent radiochemotherapy: Focus on patterns of local recurrence from the START-NEW-ERA non-randomized phase II trial
Authors: F. Arcidiacono, P. Anselmo, M. Casale, C. Zannori, V. Tassi, A. Guida, B. Enrico, M. Nunzi, M. Ragusa, F. Loreti, M. Italiani, F. Trippa
Journal: Journal of Thoracic Oncology (2025)
203P: Immunotherapy improves clinical outcome in KRAS mutated patients with unresectable NSCLC stage III: A subcohort analysis of the Austrian radio-oncological lung cancer study association regristry (ALLSTAR)
Authors: F. Zehentmayr, M. Klebermass, B. Zellinger, B. Langer, B. Grambozov, A. Purevdorj, J. Karner, G. Gruber, M. Stana, D. Minasch, K. Kirchhammer, C. Steffal, H. Stranzl, R. Moosbrugger, P. Feurstein, K. Dieckmann, E. Ruznic
Journal: Journal of Thoracic Oncology (2025)
198P: Progression patterns and survival outcomes in patients with locally advanced NSCLC after chemo-radiotherapy and durvalumab: Insights into post-progression strategies from a single institution
Authors: R. Leporati, L. Mastrodomenico, A. Bertolotti, A. Cappelli, S. Scicolone, J. Imbrescia, A. Benini, M. Palmieri, E. Cabitza, L. Trudu, G. Guaitoli, K. Di Emidio, M. Dominici, A. Bruni, F. Bertolini
Journal: Journal of Thoracic Oncology (2025)
194P: Durvalumab prolongs overall survival whereas radiation dose escalation &gt;66 Gy improves long-term local control in unresectable NSCLC stage III: Updated analysis of the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
Authors: F. Zehentmayr, P. Feurstein, E. Ruznic, B. Langer, B. Grambozov, M. Klebermass, A. Purevdorj, G. Gruber, D. Minasch, M. Heilmann, B. Breitfelder, C. Steffal, G. Gastinger-Grass, K. Kirchhammer, M. Kazil, H. Stranzl, K. Dieckmann
Journal: Journal of Thoracic Oncology (2025)
191P: Patient-reported versus clinician-reported outcomes in patients undergoing concurrent chemoradiotherapy and durvalumab maintenance for inoperable stage III NSCLC: Insights from the prospective PRECISION Study
Authors: L. Käsmann, K. Khaltar, J. Taugner, S. Mansoorian, C. Richlitzki, T. Hofer, E. Noessner, C. Schulz, M. Unterrainer, A. Tufman, F. Klauschen, A. Jung, W.G. Kunz, J. Kumbrink, N. Reinmuth, A. Holzgreve, C. Belka, F. Manapov, C. Eze
Journal: Journal of Thoracic Oncology (2025)
201P: Patient-reported outcomes (PROs) from the LAURA study: Osimertinib (osi) in patients with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) without progression after definitive chemoradiotherapy (CRT)
Authors: E. Arriola Aperribay, I. Casarini, M. Ozguroglu, M. Huang, T. Takahashi, X. Lai, K. Goto, K. Maneenil, K.H. Lee, M. Cobo Dols, N.I. Valdiviezo Lama, A. Evans, A. Bolanos, X. Huang, R. Lai, S.S. Ramalingam
Journal: Journal of Thoracic Oncology (2025)
190P: Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy (CRT) in unresectable, stage III NSCLC (urNSCLC): Final data extraction from PACIFIC-R
Authors: N. Girard, J. Bar, D. Christoph, J. Field, R. Fietkau, M.C. Garassino, P. Garrido Lopez, V.D. Haakensen, J.T.J.N. Hiltermann, S.C-H. Kao, F. McDonald, F. Mornex, M.T. Moskovitz, S. Peters, S. Siva, B. Solomon, Y. Qiao, S. Anand, P. Chander, A.R. Filippi
Journal: Journal of Thoracic Oncology (2025)
187O: A multifactorial score to predict surgical complexity of lung resection following neoadjuvant chemo-immunotherapy
Authors: M. Nardini, J. Lodhia, P. Tcherveniakov, K.N. Franks, P. Bhatnagar, K. Clarke, E. Teh, R. Milton, N. Chaudhuri, K. Papagiannopoulos, M. Callister, A. Brunelli
Journal: Journal of Thoracic Oncology (2025)
192P: Differential effect of proton pump inhibitors (PPIs) and antibiotics (ATB) on clinical outcomes from immunotherapy or placebo in patients with locally advanced, unresectable NSCLC who have not progressed following chemoradiation therapy (cCTRT): A post-hoc analysis of the PACIFIC trial
Authors: L. Brunetti, V. Santo, D.J. Pinato, B. Ricciuti, J. Naidoo, A. Nassar, H. Wakelee, K. Takada, A-R. Naqash, H.M. Abushukair, M.C. Garassino, C. Greco, S. Ramella, G. Tonini, B. Vincenzi, A. Desilets, B. Routy, A. Elkrief, L. Derosa, A. Cortellini
Journal: Journal of Thoracic Oncology (2025)
188O: Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN)
Authors: G. Pasello, M. Reck, D. Harpole, T. Mitsudomi, T. Winder, R. Zukov, G.E. Garbaos, T.V. Tran, K-Y. Lee, L. Urban, R. Lai, H. Mann, T. Fouad, J. Heymach
Journal: Journal of Thoracic Oncology (2025)
189MO: Perioperative durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIa(N2) non-small cell lung cancer: Final analysis of the trial SAKK 16/14
Authors: S.I. Rothschild, A. Zippelius, S. Hayoz, S. Chiquet, S. Savic Prince, A. Bettini, M. Frueh, C. Britschgi, L.A. Mauti, S. Peters, M.T. Mark, A.F. Ochsenbein, W-D. Janthur, C. Waibel, N. Mach, P.R. Froesch, M. Buess, P. Bohanes, M. Gonzalez, M. Pless
Journal: Journal of Thoracic Oncology (2025)
184P: 18F-BMS-986192 PET for predicting clinical response to immunotherapy in NSCLC: A novel approach beyond PD-L1 immunohistochemistry
Authors: F.J. Borm, J. Smit, S. Wiegers, N. Gerards, Y. Wang, D. Cohen, R. Boellaard, E.F. Smit, A.J. De Langen
Journal: Journal of Thoracic Oncology (2025)
1860: Pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable locally advanced non-small cell lung cancer (NSCLC): Final analysis of KEYNOTE-799
Authors: M. Reck, K.H. Lee, N. Frost, V. Breder, D.M. Kowalski, E. Levchenko, N. Reguart, A. Martinez-Marti, B. Houghton, J-B. Paoli, S. Safina, T. Komiya, A. Sanford, H. Liu, V. Novinskiy, A. Samkari, S. Jabbour
Journal: Journal of Thoracic Oncology (2025)
224P: Predictive value of FDG PET/CT parameters and T-cell subsets in stage II/III non-small cell lung cancer with neoadjuvant immunotherapy
Authors: E.S. Lee, S. Lee, S. Kim, J. Choi, J.H. Lee, J.S. Eo, H.K. Kim, H.S. Yong, S.M. Park, C-J.J. Chen, H. Robinson, P.R. Dunbar, S.Y. Lee
Journal: Journal of Thoracic Oncology (2025)
233P: Chemo-immunotherapy for borderline resectable and unresectable NSCLC
Authors: F. Cappuzzo, L. Landi, E. Garbo, A. Cooper, X. Wang, M. Mayoral, M.S. Ginsberg, L. Sholl, M. Nishino, M. Bott, E. Rendina, R. Trisolini, S. Ramella, F.T. Gallina, E. Melis, S. Buglioni, P. Ugalde, J. Chaft, M. Awad, B. Ricciuti
Journal: Journal of Thoracic Oncology (2025)
223P: Adjuvant novel tyrosine kinase inhibitors with or without platinum-based chemotherapy for resectable oncogene-addicted NSCLC: An IPD meta-analysis of phase III randomized clinical trials
Authors: R. Tajè, F.T. Gallina, D. Marinelli, D. Forcella, F. Fusco, G. Alessandrini, F.L. Cecere, L. Landi, E. Melis, V. Ambrogi, F. Cappuzzo
Journal: Journal of Thoracic Oncology (2025)
231P: Prognostic factors for survival in unresectable stage III non-small cell lung cancer (NSCLC) receiving chemoradiotherapy (CRT)
Authors: J. Zhou, F. Tohidinezhad, Y. Huang, D. De Ruysscher, L. Hendriks, P. Kalendralis, A. Lobo Gomes
Journal: Journal of Thoracic Oncology (2025)
234P: Compliance with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small cell lung cancer: A systematic review and meta-analysis
Authors: F. Guerrera, E. Balzani, F. Ambrosi, A. Di Federico, E. Faccioli, G. Facheris, R. Ferrara, A. Ferro, F. Filipello, F.T. Gallina, R. Giusti, C. Greco, M. Mammana, D. Marinelli, A. Nuccio, M. Sepulcri, G. Viscardi, P. Bertoglio
Journal: Journal of Thoracic Oncology (2025)
225P: Circulating tumor DNA as a prognostic biomarker in unresectable locally advanced NSCLC
Authors: N. Navarro-Gorro, L. Masfarre Pinto, P.F. Simoes Da Rocha, Á. Martínez, A. Taus Garcia, R. Del Rey-Vergara, S. Clave, B. Bellosillo Paricio, J. Hayes, I. Roca Carreras, F.N. Riva, E. Arriola Aperribay
Journal: Journal of Thoracic Oncology (2025)
236P: Prospective trial of immuno-(chemo)therapy prior to resection, definitive chemo-radiotherapy, or palliative therapy in patients with oligometastatic non-small cell lung cancer (KOMPASSneo)
Authors: E.J. Rhee, M. Faehling, S. Fallscheer, B. Schwenk, J. Schmiederer, J. Sträter, S. Eschmann, F. Heinzelmann, T. Kyriss
Journal: Journal of Thoracic Oncology (2025)
213P: Surgical outcomes after neoadjuvant chemo-immunotherapy for NSCLC: A systematic review and meta-analysis
Authors: L. Bertolaccini, M. Chiari, C. Bardoni, C. Diotti, G. Caffarena, S. Mohamed, A. Mazzella, M. Casiraghi, L. Spaggiari
Journal: Journal of Thoracic Oncology (2025)
230P: A retrospective analysis on patterns of surveillance after curative intent treatment for unresectable stage III non-small cell lung cancer (NSCLC)
Authors: M-F. D’Amours, E. Bhang, F.U. Usman, M-H. Denault, J. Feng, S. Kuang, A. Chan, J. Laskin, S. Sun, B. Leung, B. Melosky, H. Carolan, M. Liu, C. Ho
Journal: Journal of Thoracic Oncology (2025)
219P: Real-world outcomes of lung resections after neoadjuvant chemo-immunotherapy for resectable NSCLC: A single-center experience
Authors: F.T. Gallina, R. Tajè, F. Fusco, F.L. Cecere, L. Landi, G. Minuti, S. Buglioni, P. Visca, E. Melis, F. Cappuzzo
Journal: Journal of Thoracic Oncology (2025)
248TiP: Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemoimmunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA study)
Authors: G. Pasello, D. Scattolin, F.L. Cecere, L. Calabro, F. Grosso, G.L. Ceresoli, M. Tiseo, A. Bearz, P.A. Zucali, F. Callegarin, G. Marulli, G. De Salvo, F. Pezzuto, E. Faccioli, L. Urso, A. Tosi, S. Indraccolo, F. Calabrese, V. Guarneri, F. Rea
Journal: Journal of Thoracic Oncology (2025)
256P: 2-year survival outcomes of atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer with high tumor mutation burden: TELMA trial final report
Authors: M. Provencio Pulla, A.L.O. Ortega Granados, J. Coves Sarto, V. Calvo De Juan, R. Marse Fabregat, M. Domine Gomez, M. Guirado, E. Carcereny, N. Fernandez Nunez, R. Alvarez Cabellos, R. Blanco Guerrero, L.A. Leon Mateos, J.M. Sanchez Torres, B. Massuti Sureda, I.G. Sullivan, M.A. Cobo Dols, A. Sanchez Hernandez, C. de la Torre Cabrera, A. Cruz-Bermudez
Journal: Journal of Thoracic Oncology (2025)
257P: Stereotactic radiotherapy for oligometastatic mediastinal lymph-nodes: A multicentre retrospective experience
Authors: F. Cuccia, M. Campione, G. Mortellaro, G. Ferini, V. Zagardo, A. Viola, A. Piras, M. Truglio, A. Daidone, S. Parisi, G. Ferrantelli, G. Iatì, A. Attisano, G. Ferrera, S. Pergolizzi
Journal: Journal of Thoracic Oncology (2025)
261TiP: A single arm phase II study of PCSK9 inhibitor, alirocumab, and PD-1 inhibitor, cemiplimab, in advanced immuno-refractory metastatic non-small cell lung cancer (TOP2201)
Authors: E. Oduah, N. Ready, J. Clarke, J. Crawford, L. Alder, T. Stinchcombe, J. Rivera Concepcion, S.J. Antonia
Journal: Journal of Thoracic Oncology (2025)
262MO: Real-world validation of artificial intelligence-defined lung nodule malignancy score (qXR-LNMS) in predicting risk of lung cancer
Authors: D. Koksal, A.K. Govindarajan, H.K. Gonuguntla, S. Nayci, R. Cordova, H.Z. Mohamed, S. McCutcheon, A. Saha, P. Kantharaju, S. Sen, R. Agrawal, L. Wulandari
Journal: Journal of Thoracic Oncology (2025)
264P: Innovative portable breathomic device for early non-invasive differentiation of benign and malignant lung nodules
Authors: H. Liang, M. Peng, B. Tian, P. Fan, H. Wang, S. Chen, M. Ren, Z. Chen, R. Zhong, S. Yang, Q. Li, J. Wang, J. He
Journal: Journal of Thoracic Oncology (2025)
255P: NBTXR3 activated by SBRT in combination with nivolumab or pembrolizumab for the treatment of patients with lung metastases from NSCLC or other solid tumours in the phase I trial study 1100
Authors: C. Shen, A. Juloori, W. Stokes, J. Akulian, J. Weiss, K.S. Kirtane, L. Mayrargue, D. Rolando, R. Gineste, O.I. Vivar, G. Yang, J. Caudell, A. Sukari, N.F. Saba, S. Murgu, A. Rosenberg
Journal: Journal of Thoracic Oncology (2025)
260P: Exploring the inner and outer realms of young lung cancer: A decade of experience
Authors: R. Gullapalli, A. Santa, S.J. Rajappa, P. Nikhil, K.M. Mallavarapu, S. Kandem, R. Pinninti, P.M. Jaju, T.S. Rao, S.S. Shukla, S. Kodandapani
Journal: Journal of Thoracic Oncology (2025)
245P: The predictive and prognostic value of T- and B-cell transcriptomic signatures for clinical response to immune checkpoint blockade in pleural mesothelioma
Authors: J. van Genugten, D. Faulkner, J. Hahne, M. Disselhorst, L. Wessels, D.A. Fennell, P. Baas
Journal: Journal of Thoracic Oncology (2025)
Autonomic lysosomal escape via sialic acid modification enhances mRNA lipid nanoparticles to eradicate tumors and build humoral immune memory
Authors: Xueying Tang, Jiashuo Zhang, Yuejia Sun, Zihan Xu, Tiancheng Hang, Xinrong Liu, Yanzhi Song, Yu Zhang, Yihui Deng
Journal: Journal of Controlled Release (2025)
240P: Real-world toxicity data for the use of ipilimumab plus nivolumab in malignant mesothelioma across 11 UK centres
Authors: H. McGrath, M. Elgendy, L. Gray, A. Qaisar, A.N.M.K. Anam, Y. Mangan, H. Yusof, T. Achim, C. Ellerbie-Davies, A. Mohammed, K. Yogalingam, A. Greystoke, R. Shah, N. Steele, K. Ahmad Zaki, G.L. Banna, S. Dubash, T.R. Geldart, J. Spicer
Journal: Journal of Thoracic Oncology (2025)
On-site delivery of bioactive nanospheres utilizing lanthanides as crosslinkers and metastasis-inhibiting agents for breast cancer therapy
Authors: Yu-Chi Wang, Yan-Ting Lin, Ping-Hsun Hsieh, Chen-Wei Lai, Shuo-Fu Chen, Ming-Hong Chen, Fu-I Tung, Tse-Ying Liu
Journal: Journal of Controlled Release (2025)
Efficacy of psychosocial interventions for young offspring of parents with a serious physical or mental illness: Systematic review and meta-analysis
Authors: Giulia Landi, Kenneth I Pakenham, Zhangxuan Bao, Roberto Cattivelli, Elisabetta Crocetti, Eliana Tossani, Silvana Grandi
Journal: Clinical Psychology Review (2025)

Serious parental physical or mental illness significantly increases the risk of adverse adjustment outcomes in adolescents and young adults. This systematic review and meta-analysis evaluates the efficacy of psychosocial interventions targeting this vulnerable group. Eligible randomized control trials (RCTs) were searched through the Medline, Web of Science, PsycINFO, PsycArticles, Cinahl, and ProQuest Dissertation and Theses databases. Young offspring outcomes included: psychological (including internalizing and externalizing problems), positive, and interpersonal adjustment. Thirty-one manuscripts reporting on twenty-seven independent RCTs, including 3590 adolescent and young adult offspring, met eligibility criteria. Most of the studies targeted adolescents with a mean age within ±1 SD of 12.17-16.33 years, with only one study directly targeting young adults. Three-quarters of studies included parental mental illness, and the remaining parental physical illness. Results highlighted a small post-intervention effect for psychological adjustment (d = 0.17,[0.05,0.29], p = .006), maintained at short-term (3-12 months) follow-up (d = 0.33 [0.12,0.54], p = .002), but not at long-term (15 months or longer) follow-up (d = -0.00 [-0.19,0.19], p = .98). A similar pattern emerged for internalizing problems, while for externalizing problems, no significant post-intervention effect was detected. Results also showed a small post-intervention effect for positive adjustment (d = 0.36,[0.10,0.61], p = .006), which increased to a medium effect at short-term follow-up (d = 0.62,[0.15,1.09], p = .010). Post-intervention effects were not present for interpersonal adjustment. Intervention duration moderated effects on post-intervention outcomes, while intervention setting and gender balance moderated outcomes at follow-ups. Psychosocial interventions for young offspring of parents with serious illnesses appear effective in improving psychological and positive outcomes with small-to-moderate effects at post-intervention and short-term follow-up.
242P: SAKK 17/18 ORIGIN trial: Efficacy and safety from a multicentre phase II trial of gemcitabine and atezolizumab in pretreated patients with pleural mesothelioma
Authors: A. Rigutto, S. Hayoz, M. Frueh, S.I. Rothschild, A. Addeo, C. Britschgi, C. Waibel, F.W.F. Cerciello, V. Somasundaram, J. Musilova, S. Schaer, A. Viodé, P. Shichkova, R. Bruderer, Y. Feng, T.D.L. Nguyen-Kim, C. Zellweger, R.A.F. von Moos, M. Joerger, A. Curioni-Fontecedro
Journal: Journal of Thoracic Oncology (2025)
241P: Real-world evidence of the impact of immunotherapy (ICI) on myocarditis in p with pleural mesothelioma (PM)
Authors: S.M. Cedres Perez, I. Priano, P.F. Simoes Da Rocha, A.A. Valdivia Bustamante, P. Iranzo Gomez, N. Pardo Aranda, A. Martinez-Marti, J.G. Yaringaño Cerna, S. Torresan, E. Felip
Journal: Journal of Thoracic Oncology (2025)
239MO: Stratification of pleural mesothelioma patients for combined immunotherapy based on sarcomatoid component and tumour microenvironment markers in the IFCT-MAPS2 study
Authors: G. Tosato, Y. Blum, J-B. Assié, R. Sequeiros, A. Langlais, M. Arnould, F. Damiola, E. Amour, C. Meiller, M-C. Jaurand, A. de Reynies, V. Westeel, J. Mazieres, L. Greillier, F. Morin, S. Lantuejoul, A. Scherpereel, G. Zalcman, D. Jean
Journal: Journal of Thoracic Oncology (2025)
243P: Niraparib plus dostarlimab in pleural mesothelioma or non–small cell lung cancer harboring HRR gene mutations: Updated analysis from the UNITO-001 phase II trial
Authors: G. Farinea, L. Righi, A. Listi, F. Benso, E. Capelletto, P. Bironzo, G. Minuti, G. Pasello, A. Catino, S. Novello, G. Scagliotti, F. Passiglia
Journal: Journal of Thoracic Oncology (2025)
238TiP An update on the CONCORDE study: A phase Ib platform study of DNA damage repair inhibitors (DDRIs) in combination with conventional radiotherapy in NSCLC
Authors: A. Horne, G. Walls, S. Brown, A. Chalmers, K.N. Franks, S. Harrow, A. Hassani, M. Hatton, C. Hiley, J. Kendall, J. McAleese, M. Norris, O. Ojo, J.B. Oughton, R.H. Phillip, P. Rudd, P.H. Shaw, F. Walker, A. Greystoke, C. Faivre-Finn
Journal: Journal of Thoracic Oncology (2025)
293P: 22 years of cardiovascular mortality in U.S. adults with lung cancer: Insights from national CDC data
Authors: M.A. Mukesh, H. Ahmad, M.Z.J. Kakakhel, M.F. Ali, M.F. Tahir, K. Abdul Rehman, J. Ikram, H. Jawad, R. Ahmed
Journal: Journal of Thoracic Oncology (2025)
298P: Validation of the lung immune prognostic index (LIPI) in extensive-stage small cell lung cancer (esSCLC): Post hoc analysis of the CASPIAN and IMpower133 phase III trials
Authors: E. Auclin, M. Roulleaux Dugage, T. Gorria, J.C. Laguna Montes, A.F. Navarro Mendivil, P. Lavaud, S. Cousin, B. Besse, L. Mezquita
Journal: Journal of Thoracic Oncology (2025)
283P: I3LUNG AI-driven cough analysis: A novel tool for non-small cell lung cancer detection
Authors: C. Giangregorio, C.M. Licciardello, L. Provenzano, V. Miskovic, A. Iacobucci, P. Ambrosini, L. Ferrari, A.D. Dumitrascu, L. Mazzeo, M. Ganzinelli, T. Beninato, M. Brambilla, C. Proto, G. Corrao, S. Ferrante, G. Lo Russo, A. Pedrocchi, M.C. Garassino, E. Ambrosini, A. Prelaj
Journal: Journal of Thoracic Oncology (2025)
287P: From reactive to proactive lung cancer service delivery model: Implementation of rapid access lung lesion clinic (RALLC) and its clinical impact in a large, regional cancer centre in Australia
Authors: W. Faisal, H.L. Yeoh, E. Malsem, B. Harrap, D. Entesari-Tatafi, D. Low, K. McCann
Journal: Journal of Thoracic Oncology (2025)
302P: Phase II study of the efficacy and safety of BNT327/PM8002 plus systemic chemotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC)
Authors: Y. Cheng, J. Shi, X. Meng, L. Sun, D. Lv, X. Li, Y. Pan, J. Fang, J. Chen, X. Qi, B. Liu, P. Zhang
Journal: Journal of Thoracic Oncology (2025)
275P: Multiomic biomarkers to predict and intercept inflammation to lung cancer transition
Authors: M. Fidelle, D. Suissa, A. Renneville, T. Ben Ahmed, P. Abdayem, S. Durand, O. Caron, O. Mercier, L. Derosa, B. Geoerger, G. Kroemer, D. Drubay, S. Delaloge, D. Boulate, L. Zitvogel
Journal: Journal of Thoracic Oncology (2025)
299P: First-line (1L) durvalumab (D) + platinum-etoposide (EP) in extensive-stage SCLC (ES-SCLC): Final results and exploratory biomarker analyses from LUMINANCE
Authors: N. Reinmuth, M. Ozguroglu, N. Leighl, V. Longo, I. Hacibekiroglu, J. Roubec, M.A.N. Sendur, E. Bria, I. Cicin, S. Kilickap, S. Novello, P. Opalka, R. Ruseva, S. Lang, U. Emeribe, M. Xie, Y. Shrestha, N. Donner, F. De Marinis
Journal: Journal of Thoracic Oncology (2025)
296P: Circulating progastrin (hPG80): A versatile blood-based biomarker for all stages of non-small cell lung cancer management
Authors: E. Azkona Uribelarrea, J. Aurrekoetxea Oribe, X. Mielgo Rubio, R. Casas Cornejo, B. Ortega Gallastegi, M.G. Toribio, M.B. Calvo Martínez
Journal: Journal of Thoracic Oncology (2025)
277P: Preliminary results of LC-SHIELD study: Lung cancer screening in high risk non-smokers with artificial intelligence device
Authors: S.C.M. Li, J.W.Y. Chan, A. Chang, J. Ngai, A.H. Cheung, M.L. Wong, K. Mok, C. Tang, K. Lau, K. Lam, T.T.A. Kwong, C. Lee, C. Wong, Y. Zhang, Y. Zhang, N. Lee, W. Wong, T.S.K. Mok, C. Ng, R. Lau
Journal: Journal of Thoracic Oncology (2025)
297MO: Patterns of disease progression with durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Results from ADRIATIC
Authors: S. Senan, Y. Cheng, D.R. Spigel, B.C. Cho, K. Laktionov, Y. Zenke, K.H. Lee, A.F. Navarro Mendivil, I. Okamoto, S. Sezgin Goksu, A. Badzio, A. Shi, M. Zemanova, N. Reinmuth, P. Iyengar, L. Paz-Ares, J. Chen, W.C.V. Lai, P. Chugh, Y. Chen
Journal: Journal of Thoracic Oncology (2025)
291P: Preliminary results of cytisine therapy and tobacco cessation program in the Italian lung cancer screening program
Authors: M. Cani, U. Pastorino, E. Mercadante, C. Battiloro, A. Smedile, V. Barbieri, G.L. Pariscenti, P. Gallina, D. Bafunno, A. Moretta, A. Defilippis, A. Cammarota, G. Milanese, P. Pattacini, D. Patanè, O. Caffo, K. Ferrari, S. Novello
Journal: Journal of Thoracic Oncology (2025)
286P: Overcoming biomarker testing barriers for non-small cell lung cancer (NSCLC): OncoCollective insights into improving patient outcomes in Europe (EU)
Authors: A. Bayle, G. Morgan, M.S. Aapro, M. Calandri, A. Cardone, A. Ferris, P.J. Lamy, M. Maio, A. Palmer, R. Price, L. Shi, E. Szmytke, K. Paranjpe, C. Fernandez, H. Hansen, A. Lopez Galnares, M. Caschetta, R. Goeckeler, E. Lee
Journal: Journal of Thoracic Oncology (2025)
295P: Analytical and clinical validation of a cost-effective ctDNAbased assay for lung cancer detection
Authors: C.V.T. Nguyen, H.D. Vo, T.H. Tran, N.T. Pham, H.T. Nguyen, T.V. Phan, T.H. Dao, H.T.P. Nguyen, D.L-H. Nguyen, D-S. Nguyen, S. Tang, H. Giang, D. Phan, H-N. Nguyen, L.S. Tran
Journal: Journal of Thoracic Oncology (2025)
271P: When cancer and infection collide: Mortality trends in pneumonia and lung cancer (1999–2020)
Authors: M.M. Elbadrawy, H. Ahmad, M.Z.J. Kakakhel, P.K. Singh, R. Akhtar, A.A.A. Cheema, I. Khan, F. Naveed, M.A. Keen, J. Ikram, H. Jawad, R. Ahmed
Journal: Journal of Thoracic Oncology (2025)